Deutsche Bank Reiterates Buy on Pfizer

Deutsche Bank maintains its Buy rating on Pfizer Inc. (NYSE: PFE) as Eliquis, whose sales would be split with BMY, gained priority review.

Deutsche Bank comments, “Both companies had requested expedited review based upon the ARISTOTLE study which demonstrated that Eliquis was SUPERIOR to warfarin, and had a survival benefit. We don't think it was baked into general expectations that an expedited review would be granted, hence the drug likely gets on the market six months earlier than many had expected.”

PFE closed at $19.09 on Monday.